Metastasis to bone: causes, consequences and therapeutic opportunities (original) (raw)

• Wingo, P. A., Tong, T. & Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin. 45, 8–30 (1995).
  Article CAS Google Scholar
• Mantyh, P. W., Clohisy, D. R., Kotzenburg, M. & Hunt, S. P. Molecular mechanisms of cancer pain. Nature Rev. Cancer 2, 201–209 (2000).
  Article Google Scholar
• Honore, P. et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med. 6, 521–528 (2000).Evidence that the bone-resorption inhibitor osteoprotegerin inhibits not just osteolysis but also bone pain in metastatic bone disease.
  Article CAS Google Scholar
• Boyde, A., Maconnachie, E., Reid, S. A., Delling, G. & Mundy, G. R. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan. Electron Microsc., 1537–1554 (1986).This paper shows, by scanning electron microscopy, evidence of osteoclastic resorption pits at bone metastatic sites, indicating the importance of osteoclasts as cellular mediators of osteolysis.
• Stewart, A. F. et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J. Clin. Endocrinol. Metab. 55, 219–227 (1982).Histomorphometric evidence of the abnormalities in osteoblastic and osteolytic activity that occurs in patients with bone metastases. This was shown by observing the impaired osteoblastic response to increased osteoclastic resorption.
  Article CAS Google Scholar
• Charhon, S. A. et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51, 918–924 (1983).
  Article CAS Google Scholar
• Garnero, P. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858–864 (2000).
  Article CAS PubMed Google Scholar
• Koga, H. et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39, 1–7 (1999).
  Article CAS Google Scholar
• Koizumi, M. et al. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br. J. Cancer 75, 1601–1604 (1997).
  Article CAS PubMed Google Scholar
• Percival, R. C. et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol. 13, 41–49 (1987).One of the first studies to indicate that osteoblastic metastases are accompanied by increased bone resorption in patients with prostate cancer.
  CAS Google Scholar
• Yoshida, K. et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80, 1760–1767 (1997).
  Article CAS Google Scholar
• Pelger, R. C., Hamdy, N. A., Zwinderman, A. H., Lycklama a Nijeholt, A. A. & Papapoulos, S. E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22, 403–408 (1998).
  Article Google Scholar
• Yi, B. et al. PDGF in breast cancer promotes osteosclerotic bone metastases. J. Bone Min. Res. 15 (Suppl 1) A1035 (2000).
  Google Scholar
• Adami, S. Bisphosphonates in prostate carcinoma. Cancer 80, 1674–1679 (1997).
  Article CAS Google Scholar
• Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour–host interface. Nature 411, 375–379 (2001).An excellent review that cites evidence for the importance of the stroma in cancer-cell behaviour at primary and metastatic sites.
  Article CAS Google Scholar
• Liotta, L. A. & Kohn, E. Cancer invasion and metastases. JAMA 263, 1123–1126 (1990).
  Article CAS Google Scholar
• Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38, 2651–2660 (1978).
  CAS Google Scholar
• Zetter, B. R. The cellular basis of site-specific tumor metastasis. N. Engl. J. Med. 322, 605–612 (1990).
  Article CAS PubMed Google Scholar
• Southby, J. et al. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. 50, 7710–7716 (1990).
  CAS Google Scholar
• Powell, G. J. et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 51, 3059–3061 (1991).Clinical data that shows evidence for increased PTHrP expression in bone metastatic sites in patients with breast cancer.
  CAS Google Scholar
• Bryden, A. A., Hoyland, J. A., Freemont, A. J., Clarke, N. W. & George, N. J. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br. J. Cancer 86, 322–325 (2002).
  Article CAS PubMed Google Scholar
• Miki, T., Yano, S., Hanibuchi, M. & Sone, S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol. Res. 12, 209–217 (2001).
  Article Google Scholar
• Henderson, M. et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J. Natl Cancer Inst. 93, 234–237 (2001).
  Article CAS Google Scholar
• Guise, T. A. et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast-cancer-mediated osteolysis. J. Clin. Invest. 98, 1544–1549 (1996).Human breast cancer cells, when inoculated into the systemic circulation of nude mice, cause osteolytic lesions that are abrogated by neutralizing antibodies to the tumour peptide PTHrP.
  Article CAS PubMed Google Scholar
• Stewart, A. F. PTHrP (1–36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19, 303–306 (1996).
  Article CAS Google Scholar
• Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S. & Fuqua, S. A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57, 1244–1249 (1997).
  CAS Google Scholar
• De Larco, J. E. et al. A potential role for IL-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158, 639–646 (2001).
  Article CAS PubMed Google Scholar
• Downey, S. E. et al. Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J. Pathol. 183, 212–217 (1997).
  Article CAS Google Scholar
• Gallwitz, W. E. et al. Low doses of 6-thioguanine and 6–mercaptoguanosine inhibit osteolytic bone disease caused by human breast cancer. J. Bone Min. Res. 15 (Suppl. 1), S200 (2000).
  Google Scholar
• Ogata, E. PTHrP, paraneoplastic syndrome and cancer metastasis. J. Bone Min. Metab, 19 (Suppl. 1), S1–S2 (2001).
  Google Scholar
• Zhang, J. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235–1244 (2001).
  Article CAS PubMed Google Scholar
• Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944–949 (1995).
  Article CAS Google Scholar
• Yin, J. J. et al. Endothelin A receptor blockade inhibits osteoblastic metastases. J. Bone Min. Res. 15 (Suppl. 1), 1254 (2000).
  Google Scholar
• Yin, J. J. et al. Osteoblastic bone metastases: tumor-produced endothelin-1 mediates new bone formation via the endothelin A receptor. J. Back Musculoskeletal. Rehabil. 14 (Suppl. 1), F400 (1999).Data confirming the molecular mechanisms that are responsible for the 'vicious cycle' in breast cancer metastasis to bone.
  Google Scholar
• Marcelli, M. et al. A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. J. Clin. Invest. 85, 1522–1528 (1990).
  Article CAS PubMed Google Scholar
• Marquardt, H., Lioubin, M. N. & Ikeda, T. Complete amino acid sequence of human transforming growth factor type-β2. J. Biol. Chem. 262, 12127–12131 (1987).
  CAS Google Scholar
• Harris, S. E. et al. Effects of transforming growth factor-β on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type 1 collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Miner. Res. 9, 855–863 (1994).
  Article CAS Google Scholar
• Rabbani, S. A. et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. Commun. 173, 1058–1064 (1990).
  Article CAS Google Scholar
• Achbarou, A. et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54, 2372–2377 (1994).
  CAS Google Scholar
• Rabbani, S. A. et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267, 14151–14156 (1992).
  CAS Google Scholar
• Dallas, S. L. et al. Characterization and autoregulation of latent TGF-β complexes in osteoblast-like cell lines: production of a latent complex lacking the latent TGF-β-binding protein (LTBP). J. Biol. Chem. 269, 6815–6822 (1994).
  CAS Google Scholar
• Dallas, S. L. et al. Dual role for the latent transforming growth actor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J. Cell Biol. 131, 539–549 (1995).
  Article CAS Google Scholar
• Cramer, S. D., Chen, Z. & Peehl, D. M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156, 526–531 (1996).
  Article CAS Google Scholar
• Iwamura, M., Hellman, J., Cockett, A. T., Lilja, H. & Gershagen, S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317–325 (1996).
  Article CAS Google Scholar
• Matuo, Y. et al. Heparin binding affinity of rat prostate growth factor in normal and cancerous prostate: partial purification and characterization of rat prostate growth factor in the Dunning tumor. Cancer Res. 47, 188–192 (1987).
  CAS Google Scholar
• Mansson, P. E. et al. HBGF1 gene expression in normal rat prostate and two transplantable rat prostate tumors. Cancer Res. 49, 2485–2494 (1989).
  CAS Google Scholar
• Canalis, E. et al. Effects of endothelial cell growth factor on bone remodeling in vitro. J. Clin. Invest. 79, 52–58 (1987).
  Article CAS PubMed Google Scholar
• Canalis, E., Centrella, M. & McCarthy, T. Effects of basic fibroblast growth factor on bone formation in vitro. J. Clin. Invest. 81, 1572–1577 (1988).
  Article CAS PubMed Google Scholar
• Mayahara, H. et al. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9, 73–80 (1993).
  Article CAS Google Scholar
• Dunstan, C. R. et al. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J. Bone Miner. Res. 14, 953–959 (1999).
  Article CAS Google Scholar
• Izbicka, E. et al. Human amniotic tumor which induces new bone formation in vivo produces a growth regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor (bFGF). Cancer Res. 56, 633–636 (1996).
  CAS Google Scholar
• Yi, B., Williams, P. J., Niewolna, M., Wang, Y. & Yoneda, T. Tumor-derived PDGF-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 62, 917–923 (2002).
  CAS Google Scholar
• Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571–573 (1889).The classical paper describing the 'seed and soil' hypothesis of tumour-cell metastasis.
  Article Google Scholar
• Yin, J. J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197–206 (1999).
  Article CAS PubMed Google Scholar
• Hiraga, T., Williams, P. J., Mundy, G. R. & Yoneda, T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61, 4418–4424 (2001).
  CAS Google Scholar
• Rasmussen, A. A. & Cullen, K. J. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res. Treat. 47, 219–233 (1998).
  Article CAS Google Scholar
• Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92, 1472–1489 (2000).
  Article CAS Google Scholar
• Sasaki, A. et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55, 3551–3557 (1995).In a preclinical model of human breast cancer metastasis to bone, bisphosphonates reduce not only osteolysis but also tumour burden.
  CAS Google Scholar
• Diel, I. J. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339, 357–363 (1998).The authors show, in a controversial study, that the bisphosphonate clodronate reduces tumour burden in both bone and non-bone metastatic sites in patients with breast cancer.
  Article CAS Google Scholar
• Powles, T. J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 91, 730 (1999).
  Article CAS Google Scholar
• Saarto, T., Blomqvist, C., Virkkunen, P. & Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19, 10–17 (2001).
  Article CAS Google Scholar
• Griepp, P. et al. A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN–0007) causes a profound and sustained decrease of bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood 92 (Suppl. 1), A3227 (1998).
  Google Scholar
• Oyajobi, B. O. et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor-κB–IgG-Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61, 2572–2578 (2001).
  CAS Google Scholar
• Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nature Rev. Cancer 2, 175–187 (2002).
  Article CAS Google Scholar
• Seyberth, H. W. et al. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N. Engl. J. Med. 293, 1278–1283 (1975).
  Article CAS Google Scholar
• Lee, M. V., Fong, E. M., Singer, F. R. & Guenette, R. S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61, 2602–2608 (2001).
  CAS Google Scholar
• Sanders, J. L. et al. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141, 4357–4364 (2000).
  Article CAS Google Scholar
• Sanders, J. L., Chattopadhyay, N., Kifor, O., Yamaguchi, T. & Brown, E. M. Ca2+-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am. J. Physiol. Endocrinol. Metab. 281, E1267–E1274 (2001).
  Article CAS Google Scholar
• Moseley, J. M. et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc. Natl Acad. Sci. USA 84, 5048–5052 (1987).
  Article CAS Google Scholar
• Stewart, A. F., Wu, T., Goumas, D., Burtis, W. J. & Broadus, A. E. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem. Biophys. Res. Commun. 146, 672–678 (1987).
  Article CAS Google Scholar
• Strewler, G. J. et al. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase stimulating proteins: idenfication of parathyroid hormone-unlike domains. Biochem. Biophys. Res. Commun. 146, 672–678 (1987).
  Article Google Scholar
• Yates, A. J. P. et al. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J. Clin. Invest. 81, 932 (1988).
  Article CAS PubMed Google Scholar
• Mundy, G. R. Calcium Homeostasis: Hypercalcemia and Hypocalcemia 2nd edn (Martin Dunitz, London, 1990).
  Google Scholar
• Mundy, G. R., Wilkinson, R. & Heath, D. A. Comparative study of available medical therapy for hypercalcemia of malignancy. Am. J. Med. 74, 421–432 (1983).
  Article CAS Google Scholar
• Silverman, I. E. & Flynn, J. A. Images in clinical medicine. Ivory vertebra. N. Engl. J. Med. 338, 100 (1998).
  Article CAS Google Scholar
• Fidler, I. J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl Cancer Inst. 87, 1588–1592 (1995).
  Article CAS Google Scholar